Evaluation of teicoplanin drug utilization based on attribute hierarchical model
Objective To establish the DUE criteria for teicoplanin in patients infected objectively,and evaluate the rationality of clinical practice of teicoplanin based on AHM comprehensively.Methods The DUE criteria of teicoplanin were established based on the drug instructions,related clinical guidelines and expert consensus.The archived cases of 183 patients treated with teicoplanin for injection in the hospital from October 2022 to December 2023 were analyzed and evaluated by AHM.Results The top 3 reasons for the irrationality rate of teicoplanin were 155 cases(84.70% )of administered dose,124 cases(67.76% )of adverse reactions,and 110 cases(60.11% )of co-medication.Through scoring the cases,MRS<60 was 43 cases(23.50% ),60≤MRS<80 was 99 cases(54.10% ),80≤MRS<90 was 27 cases(14.75% ),and≥90 was 14 cases(7.65% ),respectively.The average score was 69.19.Conclusion The rational use of teicoplanin in Northern Jiangsu People's Hospital was not up to the mark.The rational clinical application of teicoplanin,including administration dosage,drug adverse reaction,combination of medication,remains to be improved.Targeted intervention measures such as administration dose optimization,adverse reaction management strengthening and combined drug use standardization should be taken to further strengthen the rational supervision of drug use,and effective measures needs to be taken to target intervention,so as to improve the safety and effectiveness of the use of teicoplanin.
teicoplaninattribute hierarchical modeldrug use evaluationrationality evaluationadministration dose
NETL
NSTL
万方数据
